Leica's GM To Head Epistem
This article was originally published in Clinica
Epistem Holdings, the personalized medicine specialist, has appointed David Budd CEO and director. Budd, who officially assumes the position in mid-April, will replace Matthew Walls, who resigned in October last year. The new CEO brings to the Manchester, UK company over 20 years’ experience launching multiple diagnostic products into international markets. He joins from Leica Biosystems (a Danaher company) where he most recently served as general manager of its Amsterdam operations. Prior to Leica, Budd has also held senior commercial roles at Siemens Healthcare Diagnostics, Bayer Diagnostics and Visible Genetics. Epistem’s chairman, Ian Gilham, will continue to serve as interim CEO until Budd joins the company. Epistem’s flagship product is Genedrive, a portable PCR instrument designed for rapid, point of care diagnosis. The initial indications which the firm is targeting are tuberculosis and hepatitis C.